

## Phospholipase C-related but Catalytically Inactive Protein Is Required for Insulin-induced Cell Surface Expression of $\gamma$ -Aminobutyric Acid Type A Receptors

Fujii, Makoto

Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University

Kanematsu, Takashi

Department of Dental Pharmacology, Graduate School of Biomedical Sciences, Hiroshima University | Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University

Ishibashi, Hitoshi

Department of Developmental Physiology, National Institute for Physiological Sciences

Fukami, Kiyoko

Laboratory of Genome and Biosignal, Tokyo University of Pharmacy and Life Science

他

<https://hdl.handle.net/2324/26453>

---

出版情報 : Journal of Biological Chemistry. 285 (7), pp.4837-4846, 2010-02-12. American Society for Biochemistry and Molecular Biology

バージョン :

権利関係 : (C) 2010 by The American Society for Biochemistry and Molecular Biology, Inc.

## Phospholipase C-related but catalytically inactive protein is required for insulin-induced cell surface expression of $\gamma$ -aminobutyric acid type A receptors

Makoto Fujii<sup>1</sup>, Takashi Kanematsu<sup>1,8</sup>, Hitoshi Ishibashi<sup>2</sup>, Kiyoko Fukami<sup>3</sup>, Tadaomi Takenawa<sup>4</sup>, Keiichi I. Nakayama<sup>5</sup>, Stephen J. Moss<sup>6</sup>, Junichi Nabekura<sup>2</sup> and Masato Hirata<sup>1,\*</sup>

From <sup>1</sup>Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, and Station for Collaborative Research, Kyushu University, Fukuoka 812-8582, Japan

<sup>2</sup>Department of Developmental Physiology, National Institute for Physiological Sciences, Okazaki 444-8585, Japan

<sup>3</sup>Laboratory of Genome and Biosignal, Tokyo University of Pharmacy and Life Science, Tokyo 192-0392, Japan

<sup>4</sup>Department of Lipid Biochemistry, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan

<sup>5</sup>Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan

<sup>6</sup>Department of Neuroscience, Tufts University School of Medicine, Boston, MA 02111 USA

\*Corresponding author;

M. H.; TEL: +81-92-642-6317, FAX: +81-92-642-6322, E-mail: hirata1@dent.kyushu-u.ac.jp

Running Title: PRIP and GABA<sub>A</sub> receptor trafficking

The  $\gamma$ -aminobutyric acid type A (GABA<sub>A</sub>) receptors play a pivotal role in fast synaptic inhibition in the central nervous system. One of the key factors for determining synaptic strength is the number of receptors on the postsynaptic membrane, which is maintained by the balance between cell surface insertion and endocytosis of the receptors. In this study, we investigated whether phospholipase C-related but catalytically inactive protein (PRIP) is involved in insulin-induced GABA<sub>A</sub> receptor insertion. Insulin potentiated the GABA-induced Cl<sup>-</sup> current ( $I_{GABA}$ ) by about 30% in wild-type neurons, but not in PRIP1 and PRIP2 double-knockout (DKO) neurons, suggesting that PRIP is involved in insulin-induced potentiation. The phosphorylation level of the GABA<sub>A</sub> receptor  $\beta$  subunit was increased by about 30% in the wild-type neurons but not in the mutant neurons, which were similar to the changes observed in  $I_{GABA}$ . We also revealed that PRIP recruited active Akt to the GABA<sub>A</sub> receptors by forming a ternary complex under insulin stimulation. The disruption of the binding between PRIP and the GABA<sub>A</sub> receptor  $\beta$  subunit by PRIP interference peptide attenuated

the insulin-potentiation of  $I_{GABA}$ . Taken together, these results suggest that PRIP is involved in insulin-induced GABA<sub>A</sub> receptor insertion by recruiting active Akt to the receptor complex.

The  $\gamma$ -aminobutyric acid (GABA<sup>†</sup>) type A (GABA<sub>A</sub>) receptors are GABA-gated chloride channels that mediate the majority of fast synaptic inhibition in the central nervous system (1-5). The perturbation of GABA-GABA<sub>A</sub> receptors-mediated neurotransmission causes several central nervous system disorders including motor coordination, anxiety, insomnia, schizophrenia, and epilepsy. Additionally, GABA<sub>A</sub> receptors are important therapeutic drug targets for sedative, anxiolytic, anticonvulsant, and hypnotic agents (1-5). Therefore, it is important to uncover how synaptic strength is regulated in GABAergic transmission. The GABA<sub>A</sub> receptors are heteropentamers composed of a combination of 18 GABA<sub>A</sub> receptor subunits, which are divided into seven subunit classes ( $\alpha$ 1-6,  $\beta$ 1-3,  $\gamma$ 1-3,  $\delta$ ,  $\epsilon$ 1-3,  $\theta$ , and  $\pi$ ) based on their sequence homology (1-5). Each receptor subunit has a similar structure with a large N-terminal extracellular region, which is the binding site

for GABA and psychoactive drugs such as benzodiazepines, followed by four hydrophobic transmembrane domains (TM1-4) with a large intracellular loop region between TM3 and 4. This intracellular loop region is a target for protein-protein interactions, phosphorylation, ubiquitination, and palmitoylation, which control receptor trafficking, stability, and clustering on the synaptic membrane (1-5). Regulation of the number of receptors on the postsynaptic membrane is one of the key factors for determining synaptic strength, which is maintained by a balance between the insertion and endocytosis of receptors to/from the cell surface. Recently, it was reported that the dephosphorylation of the GABA<sub>A</sub> receptor  $\beta$  or  $\gamma 2$  subunit triggers endocytosis by facilitating the binding to the  $\mu 2$  subunit of adaptor protein 2 (AP2) complex, a critical component of clathrin-dependent endocytosis (6-9). On the other hand, it was reported that insulin stimulates GABA<sub>A</sub> receptor insertion into the cell surface membrane *via* Akt-mediated phosphorylation of the GABA<sub>A</sub> receptor  $\beta$  subunit (10-14).

We previously identified a new inositol 1,4,5-triphosphate binding protein from rat brain lysate by affinity column chromatography (15). Our subsequent studies on the characterization of the protein revealed that 1) it has a domain organization similar to  $\delta$ -type phospholipase C (PLC) but has no PLC activity, which is the reason for its name, PRIP (PLC-related but catalytically inactive protein) (16, 17). 2) PRIP has two isoforms, PRIP1 and 2, which are expressed mainly in the brain and ubiquitous organs, respectively (18-20). 3) PRIP knockout mice are less sensitive to benzodiazepine-type drugs, such as diazepam, suggesting that the cell surface expression of  $\gamma$  subunit-containing GABA<sub>A</sub> receptors is diminished in these mutant mice (21, 22). 4) PRIP facilitates GABA<sub>A</sub> receptor-associated protein (GABARAP) mediated cell surface expression of  $\gamma 2$  subunit-containing GABA<sub>A</sub> receptors by acting as a bridging molecule between GABARAP and receptors (22-24). 5) PRIP regulates the phosphorylation level of the GABA<sub>A</sub> receptor  $\beta$  subunit by binding to protein phosphatases (25-27). 6) PRIP is involved in clathrin-dependent constitutive

endocytosis of GABA<sub>A</sub> receptors (28). We also have reported that PRIP modulates brain-derived neurotrophic factor (BDNF)-induced GABA<sub>A</sub> receptor endocytosis through the regulation of the receptor phosphorylation level (29). These results suggest that PRIP regulates GABA<sub>A</sub> receptor function through receptor trafficking, phosphorylation, and endocytosis (30, 31).

In this study, we investigated whether PRIP is involved in insulin-induced GABA<sub>A</sub> receptor insertion. Insulin potentiated the GABA-induced Cl<sup>-</sup> current ( $I_{GABA}$ ) by about 30% in wild-type (WT) hippocampal neurons but not in neurons derived from PRIP1 and PRIP2 double-knockout (DKO) mice. The phosphorylation level of the  $\beta$  subunit was increased by about 30% in the WT neurons but not in the DKO neurons, which was similar to the changes observed in  $I_{GABA}$ . Using an immunoprecipitation assay and a glutathione S-transferase (GST) pull down assay using brain lysate together with a HEK293 reconstitution system we revealed that PRIP recruited active Akt to GABA<sub>A</sub> receptors. The disruption of the binding between PRIP and the  $\beta$  subunit by PRIP interference peptide attenuated the insulin-potentiated  $I_{GABA}$ . Interestingly, pre-treatment with brefeldin A (BFA), an inhibitor of anterograde trafficking from the ER to the Golgi (32, 33) decreased  $I_{GABA}$  under insulin treatment. Collectively, these results suggest that PRIP plays an important role in insulin-induced GABA<sub>A</sub> receptor insertion by recruiting active Akt to the receptor complex.

## EXPERIMENTAL PROCEDURES

*Chemicals, Plasmids, and Animals* - Insulin and okadaic acid were obtained from Wako. Wortmannin, BFA, and crosstide were purchased from Sigma. PRIP1 553-565 peptide and its scrambled peptide were described previously (29). Anti-PRIP1 and anti-PRIP2 polyclonal antibodies were described previously (20, 21). Anti-Akt polyclonal antibody, anti-phosphoAkt (T308 or S473) polyclonal antibodies, and anti-insulin receptor  $\beta$  subunit monoclonal antibody (clone 4B8) were purchased from Cell Signaling. Anti-GABA<sub>A</sub> receptor  $\alpha 1$

subunit and anti-GABA<sub>A</sub> receptor  $\gamma$ 2 subunit polyclonal antibodies were obtained from Alpha Diagnostic International. Anti-GABA<sub>A</sub> receptor  $\beta$ 2/3 subunit monoclonal antibody (clone 62-3G1) and anti-N-ethylmaleimide-sensitive factor (NSF) polyclonal antibody were from Upstate. Anti-GST polyclonal antibody was purchased from Santa Cruz Biotechnology. Horseradish peroxidase (HRP)-conjugated anti-rabbit and anti-mouse IgG were obtained from GE Healthcare. [<sup>32</sup>P]Orthophosphate (5.55 GBq/ml) and [ $\gamma$ -<sup>32</sup>P]ATP (185 MBq/ml, specific activity: 111 TBq/mmol) were purchased from PerkinElmer. Construction of the mammalian expression vectors for the MYC- and FLAG-tagged GABA<sub>A</sub> receptor subunit ( $\alpha$ 1,  $\beta$ 2, and  $\gamma$ 2S) was described previously (34). Briefly, the MYC- or FLAG-tag was introduced between amino acids 4 and 5 of the mature form of each receptor subunit. For the mammalian GST fusion protein expression vector pcDNA3.1(-)/GST1, GST was amplified using primers M-81, 5' AAA AAG CTA GCC ACC ATG TCC CCT ATA CTA GG 3' (underlining denotes the NheI site) and M-82, 5' AAA AAC TCG AGA TCG ATA CCG TCG ACC TCG A 3' (underlining denotes the XhoI site) and pGST4 as a template. The PCR products were digested using NheI/XhoI and cloned into the same sites of pcDNA3.1(-). The rat PRIP1 (rPRIP1) was amplified using primers M-85, 5' AAA AAC TCG AGC ATG GCT GAG GGC GCG GCT A 3' (underlining denotes the XhoI site) and M-86, 5' AAA AAA AGC TTT CAC AAC TTC CCG TTC TCT TC 3' (underlining denotes the HindIII site) and pcMT31 (16) as a template. The PCR products were digested using XhoI/HindIII and cloned into the same sites of pcDNA3.1(-)/GST1 to produce pcDNA3.1(-)/GST1-rPRIP1. The PRIP1 expression plasmid pSG5/rPRIP1 was described previously (16). The mammalian expression vector for Akt pECE/Akt was kindly provided by Dr. U. Kikkawa (Kobe University, Japan) (35). The generation of the DKO mice was described previously (22, 29). The handling of the mice and all procedures were approved by the Animal Care Committee of Kyushu University, according to the guidelines of the Japanese

Council on Animal Care.

*Electrophysiology* - Electrophysiological measurements were performed in acutely isolated hippocampal CA1 pyramidal neurons using the conventional whole-cell patch-clamp technique. The acutely dissociated neurons were prepared from postnatal day 10-14 WT or DKO mice, as described previously (36). All recordings were performed under voltage clamp conditions at a holding potential of -50 mV and a patch-clamp amplifier (EPC-7plus, HEKA Instruments Inc). All experiments were performed at a room temperature of 22-25°C. The ionic composition of patch pipette solution containing 80 mM KCl, 70 mM K-methanesulfonate, 4 mM ATP-Mg, 2 mM EGTA, 1 mM MgCl<sub>2</sub>, 10 mM HEPES and adjusted pH to 7.2 with Tris-base. Extracellular solution containing 150 mM NaCl, 2.5 mM KCl, 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM HEPES and 10 mM glucose. The pH was adjusted to 7.4 with Tris-base. Reagents dissolved in extracellular solution were applied by using the Y-tube perfusion system, which allows rapid exchange of the solution surrounding a cell (37, 38). All data are expressed as the means  $\pm$  standard deviation (S. D.).

*Cell Culture and Transfection* - HEK293 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10 % fetal bovine serum supplemented with 100 U/ml penicillin and 0.1 mg/ml streptomycin. The cells were maintained at 37°C in a humidified 5 % CO<sub>2</sub> incubator. Plasmid transfection was performed using the calcium phosphate method as described elsewhere (39) or Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Briefly, 1.5  $\mu$ g of each GABA<sub>A</sub> receptor subunit ( $\alpha$ 1,  $\beta$ 2, and  $\gamma$ 2S) with or without 2.5  $\mu$ g of pSG5/rPRIP1 and/or pECE/Akt were transfected into 7.5  $\times$  10<sup>5</sup> cells. For the GST pull down assay, 1.0  $\mu$ g of pcDNA3.1(-)/GST1 or pcDNA3.1(-)/GST1-rPRIP1 was transfected with 2.5  $\mu$ g of pECE/Akt. After 48 hr incubation, the cells were used for each experiment. Cortical neurons were prepared from postnatal day 0 (P0) WT or DKO mice, as described previously (21, 29) and were cultured for 14-18 days *in vitro* (DIV) before the experiments.

*Immunoprecipitation, GST-Pull Down, and Western Blotting* - Cell lysates were prepared from cortical neurons or plasmid-transfected HEK293 cells using ice-cold lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, 1 % Triton X-100, phosphatase inhibitors (50 mM NaF, 10 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub>, 20 mM β-glycerophosphate, and 1 mM Na<sub>3</sub>VO<sub>4</sub>), and protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 100 μM (*p*-amidinophenyl) methanesulfonyl fluoride hydrochloride, 10 μg/ml leupeptin, 10 μg/ml pepstatin A, and 3.4 μg/ml aprotinin). The mouse whole brain lysates of WT or DKO mice were also prepared using the same buffer. In the case of co-precipitation of NSF, 0.5 mM ATP was added to the lysis buffer. The lysates were subjected to immunoprecipitation using the indicated antibodies. For the GST-pull down assay, 20 μl of glutathione Sepharose™ 4B (GE Healthcare) were added to cell lysates expressing the GST-fusion protein. The immunocomplex was washed five times with 1 ml of ice-cold lysis buffer containing phosphatase inhibitors. The lysates and immunocomplexes were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and then transferred onto polyvinylidene fluoride membrane. Western blotting was performed using the indicated antibodies, and signals were detected using the ECL plus Western blotting detection system (GE Healthcare) and LAS3000 mini (Fuji Film).

*[<sup>32</sup>P]Labeling of Cultured Neurons* - Cultured cortical neurons (DIV 14-18) were incubated with 1 ml of phosphate-free DMEM for 1 hr and then labeled with 7.4 MBq/ml of [<sup>32</sup>P]orthophosphate for 4 hr at 37°C. The neurons were stimulated with 500 nM insulin for the indicated times at 37°C. The cells were then washed twice with ice-cold phosphate buffered saline and extracted with 500 μl of ice-cold lysis buffer containing phosphatase inhibitors and protease inhibitors. The cell lysates were subjected to immunoprecipitation using an anti-GABA<sub>A</sub> receptor β2/3 subunit monoclonal antibody. The immunocomplexes were washed five times with 1 ml of ice-cold lysis buffer containing phosphatase inhibitors and subjected to

SDS-PAGE. Phosphorylated proteins were detected by autoradiography using a Bio-Image analyzer BAS2500 (Fuji Film).

*Akt Kinase Assay* - The Akt kinase assay was described previously (40). Briefly, immunocomplexes created using an anti-Akt polyclonal antibody were washed once with ice-cold 1 ml of Akt kinase assay buffer (50 mM Tris-HCl (pH 7.5), 10 mM MgCl<sub>2</sub>, and 1 mM dithiothreitol) and then resuspended in 30 μl of the same buffer containing 100 μM peptide substrate, crosstide, and 10 μM [γ-<sup>32</sup>P]ATP (37 kBq/reaction). After incubation for 30 min at 30°C, the reaction was stopped by adding 10 μl of 300 mM H<sub>3</sub>PO<sub>4</sub>. The reaction products were spotted onto peptide binding paper (Whatman P81 cation exchange paper) and then washed three times with 75 mM H<sub>3</sub>PO<sub>4</sub> to remove non-specific radioactivity. After drying, the paper was subjected to liquid scintillation counting. Data are expressed as means ± S.D..

## RESULTS

*Insulin potentiates GABA-induced Cl<sup>-</sup> current and phosphorylation of the GABA<sub>A</sub> receptor β subunit in WT but not DKO neurons* - In this study, we investigated whether PRIP is involved in insulin-induced GABA<sub>A</sub> receptor insertion. Then, we first investigated the effect of insulin on *I*<sub>GABA</sub> using acutely isolated hippocampal CA1 neurons from either WT or DKO mice. *I*<sub>GABA</sub> was increased maximally by 30% during 15 min of 1 μM insulin stimulation in WT neurons (Fig. 1A), which is consistent with previous reports by other groups (10-13). In the DKO neurons, however, no insulin effect was observed (Fig. 1A).

We next investigated insulin-induced phosphorylation of the GABA<sub>A</sub> receptor β subunit using cortical neurons from each genotype because insulin-induced membrane insertion of GABA<sub>A</sub> receptors is accompanied by the phosphorylation of the β subunit (11, 12). For this purpose, cultured neurons were metabolically labeled with [<sup>32</sup>P]orthophosphate for 4 hr and then stimulated with 500 nM insulin for 5, 15, or 30 min. The GABA<sub>A</sub> receptor β subunits were precipitated using an anti-GABA<sub>A</sub>

receptor  $\beta 2/3$  subunit antibody, followed by separation by SDS-PAGE and autoradiography. As shown in Figure 1B, phosphorylation of the GABA<sub>A</sub> receptor  $\beta$  subunit was increased by about 30% after 5 min of insulin stimulation and continued for 30 min in WT, but no such increase in phosphorylation was observed in the DKO neurons. These results suggest that PRIP participates in the insulin-induced phosphorylation of the GABA<sub>A</sub> receptor  $\beta$  subunit, leading to the insulin-induced potentiation of  $I_{GABA}$ .

Two possible explanations for the low phosphorylation of the  $\beta$  subunit observed in DKO neurons are higher activity of phosphatases or lower activity of kinases. We previously reported that PRIP participates in the regulation of the phosphorylation level of the GABA<sub>A</sub> receptor  $\beta$  subunit by acting as a scaffolding protein for protein phosphatases (PP1 and PP2A) (27, 29). So, we investigated the effects of protein phosphatase inhibitors on the insulin-induced potentiation of  $I_{GABA}$ . We pretreated neurons with 10  $\mu$ M okadaic acid for 15 min, which inhibits both PP1 and PP2A at this concentration (42) and then measured the effect of insulin on  $I_{GABA}$ . Pretreatment with okadaic acid had no effect on  $I_{GABA}$  in the presence of insulin stimulation with DKO neurons (Fig. 2A, right panel). If higher phosphatase activity is responsible for the low phosphorylation of the  $\beta$  subunit, okadaic acid would have increased  $I_{GABA}$ . WT neurons exhibited a marginal increase of  $I_{GABA}$  insulin-potentiation, but the effect was not significant (Fig. 2A, left panel). These results indicate that the PRIP deficiency caused the failure of kinase(s) action, rather than the regulation of phosphatases.

It is well known that insulin activates the phosphatidylinositol 3-kinase (PI 3-kinase)-Akt signaling pathway (43, 44) and the Akt-mediated phosphorylation of the GABA<sub>A</sub> receptor  $\beta$  subunit, and the potentiation of miniature inhibitory postsynaptic currents (mIPSCs) is also reported to require the process (11, 12). We pretreated neurons with 100 nM wortmannin, a potent PI 3-kinase inhibitor (45) for 15 min prior to insulin stimulation. Consistent with previous reports (12, 13), pretreatment with

wortmannin completely blocked the insulin-potentiation of  $I_{GABA}$  in WT neurons (Fig. 2B, left panel), while wortmannin had no effect on the  $I_{GABA}$  in DKO neurons (Fig. 2B, right panel), confirming that the PI 3-kinase signaling pathway was required in our experiments.

*Akt activation following PI 3-kinase activation in response to insulin stimulation* - To find reasonable explanations for the failure of the phosphorylation of the GABA<sub>A</sub> receptor  $\beta$  subunit in response to insulin stimulation observed in the DKO neurons, we investigated whether PRIP deficiency impaired the insulin signaling pathway. For this purpose, we first examined the expression level of molecules involved in insulin signaling. Cortical neurons from WT or DKO mice were cultured until 14-18 DIV. After serum starvation for 4 hr, the neurons were stimulated with 500 nM insulin for 5, 15, or 30 min, and cell lysates were prepared, followed by Western blotting using relevant antibodies. As shown in Figure 3A, PRIP deficiency had no effect on the expression levels of the insulin receptor  $\beta$  subunit, Akt or several GABA<sub>A</sub> receptor subunits, and insulin stimulation for up to 30 min also had no effect on the expression of these molecules.

We then examined Akt activation in response to insulin stimulation by monitoring the Akt phosphorylation at the T308 and S473 residues using anti-phosphoAkt antibodies. As shown in Figure 3B, the phosphorylation of Akt, an index of Akt activation was increased at 5 min stimulation and sustained for 30 min, which did not differ between the WT and DKO neurons. Wortmannin completely blocked the increase in phosphoAkt (results not shown). The activity of Akt was biochemically assayed: immunoprecipitates of anti-Akt antibody attached to WT or DKO neurons stimulated with insulin for 15 min were subjected to an Akt kinase assay *in vitro* using crosstide as a substrate and [ $\gamma$ -<sup>32</sup>P]ATP. As shown in Figure 3C, the immunoprecipitates from the neurons stimulated with insulin exhibited an approximately 2-fold increase of [<sup>32</sup>P] radioactivity incorporation, and there was no significant difference between the genotypes. The results indicate that Akt kinase

activation, which is probably responsible for insulin-induced phosphorylation of the GABA<sub>A</sub> receptor  $\beta$  subunit (11, 12), was not impaired by PRIP deficiency.

*PRIP facilitates complex formation between GABA<sub>A</sub> receptors and Akt*

- Since PRIP deficiency had no effect on insulin-induced Akt activation but caused the impairment of the insulin-induced phosphorylation of the GABA<sub>A</sub> receptor  $\beta$  subunit, we hypothesized that PRIP might function as a scaffolding molecule that makes Akt more accessible to the GABA<sub>A</sub> receptor  $\beta$  subunit. To examine this possibility, we performed a co-immunoprecipitation assay using brain lysates. The brain lysates prepared from WT or DKO mice were immunoprecipitated using an anti-GABA<sub>A</sub> receptor  $\beta$ /3 subunit and then analyzed by Western blotting using anti-PRIP1, anti-PRIP2, and anti-Akt antibodies. Assessment by Western blotting of the amount of immunoprecipitated GABA<sub>A</sub> receptor  $\beta$ /3 subunits was not possible because the corresponding bands overlapped with that for the immunoglobulin heavy chain used for the immunoprecipitation. However, we confirmed in advance that the antibody we used was able to precipitate the GABA<sub>A</sub> receptor  $\beta$  subunit using a HEK293 reconstitution system with GABA<sub>A</sub> receptor subunits in combination with the [<sup>35</sup>S]methionine pulse-chase technique (results not shown). Consistent with our previous reports (27, 28), PRIP1 and 2 in the WT brain lysates were co-immunoprecipitated with the GABA<sub>A</sub> receptor  $\beta$  subunit (Fig. 4A, right panel). There were no corresponding bands for PRIP1 or 2 in the immunocomplexes produced from the DKO brain lysates (Fig. 4A, right panel). The amount of Akt co-precipitated with the GABA<sub>A</sub> receptor  $\beta$ /3 subunit was much greater in the WT lysates than in the DKO lysates (Fig. 4A, right panel), indicating that PRIP promotes complex formation between the  $\beta$ /3 subunit and Akt. It is noteworthy that PRIP deficiency caused no effect on the direct binding between GABA<sub>A</sub> receptor  $\beta$ /3 subunit and NSF, one of the  $\beta$  subunit binding proteins (46) (Fig. 4A, right panel). We next investigated whether insulin affects this complex formation, using a cultured

reconstitution system. We exogenously expressed MYC-tagged GABA<sub>A</sub> receptor subunits ( $\alpha$ 1,  $\beta$ 2, and  $\gamma$ 2S) and Akt, with or without PRIP1 in HEK293 cells, which intrinsically contain trace amounts of PRIP1 and 2. After insulin stimulation for 5, 15, or 30 min, the cell lysates were subjected to immunoprecipitation using an anti-MYC antibody, followed by Western blotting for Akt. The amount of immunoprecipitated GABA<sub>A</sub> receptors was not apparent for the same reason as mentioned above. A small amount of Akt was seen in fractions co-precipitated with GABA<sub>A</sub> receptors in the un-stimulated cells. Insulin stimulation only increased the amount of Akt co-precipitated with GABA<sub>A</sub> receptors in the PRIP-expressing cells (Fig. 4B: the left and right panels show typical blots and a summary of multiple experiments, respectively), suggesting that PRIP facilitates complex formation between the GABA<sub>A</sub> receptor and Akt under insulin stimulation.

We next examined the direct binding between PRIP1 and Akt using an *in vivo* GST pull-down assay. Genes for GST or GST-rat(r)PRIP1 were transfected with Akt into HEK293 cells. After insulin stimulation for 15 min, GST alone or GST-rPRIP1 was precipitated from the cell lysates using glutathione-conjugated beads, followed by Western blotting for Akt and phosphoAkt. As shown in Figure 4C, GST-rPRIP1, but not GST, bound to Akt when the cells were stimulated with insulin. Taken together, these results suggest that PRIP recruits phosphorylated (active) Akt to GABA<sub>A</sub> receptors by forming a ternary complex under insulin stimulation. Thus, PRIP might be implicated in Akt-dependent phosphorylation of GABA<sub>A</sub> receptors, leading to their insertion into the cell surface membrane.

*PRIP1 553-565 peptide attenuates insulin potentiation of I<sub>GABA</sub>*

- We next investigated whether such complex formation is important for the insulin-potentiation of I<sub>GABA</sub>. To address this issue, PRIP1 553-565 peptide at 3  $\mu$ g/ml, which reduces the binding between PRIP1 and GABA<sub>A</sub> receptor  $\beta$  subunit in cultured cells (29), was applied into WT neurons through a patch pipette, and then I<sub>GABA</sub> was measured in the presence of insulin. As

shown in Figure 5, the PRIP1 553-565 peptide but not the control peptide (scrambled peptide of PRIP1 553-565) partially attenuated the insulin potentiation of  $I_{GABA}$ , indicating that the association between the  $\beta$  subunit and PRIP is important for making Akt accessible to the receptor  $\beta$  subunit, resulting in the potentiation of  $I_{GABA}$ .

*BFA reverses the effect of insulin on  $I_{GABA}$*  - Insulin triggers the activation of Akt, leading to the phosphorylation of GABA<sub>A</sub> receptors, which are resistant to internalization, by inhibiting its association with AP2 complex (6-9). Therefore, the apparent potentiation of  $I_{GABA}$  observed in WT neurons could have resulted from the inhibition of insulin-induced internalization rather than insulin-induced facilitation of GABA<sub>A</sub> receptor insertion. To examine this possibility, we pretreated WT neurons with 5  $\mu$ g/ml BFA, an inhibitor of anterograde trafficking from the ER to the Golgi (32, 33) for 15 min and measured the effect of insulin on  $I_{GABA}$ . If the assumption is correct, BFA would have had little effect; however, BFA caused further decreases in  $I_{GABA}$  below the control level after insulin treatment (Fig. 6, left panel). This effect was not observed under un-stimulated conditions (time -6 to 0 min) (Fig. 6, left panel). BFA had no effect on  $I_{GABA}$  in the DKO neurons (Fig. 6, right panel). The results suggest that insulin induces both GABA<sub>A</sub> receptor insertion and subsequent endocytosis of the GABA<sub>A</sub> receptor and that this insertion mainly occurs in WT neurons. Additionally, the result indicates that PRIP is an important molecule in the mechanism that allows insulin to execute its effects on GABA<sub>A</sub> receptor trafficking.

## DISCUSSION

It has been reported that insulin triggers rapid translocation of functional GABA<sub>A</sub> receptors from the intracellular pool to the cell surface membrane, thus increasing the amplitude of GABA<sub>A</sub> receptor-mediated mIPSCs (10). The underlying molecular mechanisms have been proposed as follows: insulin elicits tyrosine phosphorylation at residues Y372 and Y379 of the  $\beta$ 2 subunit of GABA<sub>A</sub> receptors by unknown kinase(s), and these phosphotyrosines are then

recognized by the SH2 domain of p85 (13), a regulatory subunit of PI 3-kinase. The PI 3-kinase bound to GABA<sub>A</sub> receptors produces phosphatidylinositol 3,4,5-trisphosphate, an upstream activator of serine/threonine kinase Akt around the receptors, leading to the phosphorylation of the intracellular loop region of the  $\beta$  subunits (S409 in  $\beta$ 1, S410 in  $\beta$ 2, or S409 in  $\beta$ 3), which is essential for the membrane insertion of GABA<sub>A</sub> receptors (11, 12).

The current study was motivated by the finding that no effect of insulin on the potentiation of  $I_{GABA}$  was seen in neurons derived from PRIP-deficient mice, indicating that PRIP is involved in process(es) triggered by insulin stimulation. Therefore, our studies exploring the possible mechanisms in which PRIP is implicated have continued to examine each step involved in known insulin signaling pathways (43, 44). PRIP-deficiency neither perturbs protein expression profiles including those of insulin receptors and Akt nor impairs the activation of Akt in whole cell extract, as assessed by the phosphorylation of residues T308 and S473 and *in vitro* enzymatic activity using synthetic peptide substrate. However, the phosphorylation of the GABA<sub>A</sub> receptor  $\beta$  subunit in neurons from DKO mice was not augmented by insulin stimulation. This phenomenon is probably attributed to the fact that Akt is not accessible to GABA<sub>A</sub> receptor  $\beta$  subunits in the absence of PRIP. Based on the observations, we propose that PRIP functions as a scaffolding protein that presents the active form of Akt to GABA<sub>A</sub> receptors, enabling insulin signaling to potentiate  $I_{GABA}$  (Fig. 7).

We previously reported that PRIP is involved in the regulation of BDNF-induced endocytosis of GABA<sub>A</sub> receptors (29). In this case, protein kinase C (PKC), which directly associates with the GABA<sub>A</sub> receptor  $\beta$  subunit, is activated by BDNF stimulation and triggers the phosphorylation of the S408 and S409 residues of the  $\beta$ 3 subunit. These residues are subsequently dephosphorylated by PP2A, which is recruited to the vicinity of the receptors *via* PRIP (29, 41). Thus, BDNF stimulation triggers transient phosphorylation of the  $\beta$  subunit, followed by long-lasting dephosphorylation. The  $\mu$ 2



subunit of AP2 complex specifically binds to the dephosphorylated form of the  $\beta$  subunit, leading to clathrin-mediated endocytosis of the GABA<sub>A</sub> receptor (6-8). Correspondingly, a transient increase and a subsequent long-lasting decrease in  $I_{GABA}$  is observed (29, 41). On the other hand, in DKO neurons, BDNF caused a gradual increase in the phosphorylation of the  $\beta$  subunit and therefore of  $I_{GABA}$ , which lasted for the full 30 min examination period (29). Taken together, these results indicate that different extracellular stimuli evoke phosphorylation of the  $\beta$  subunit of the GABA<sub>A</sub> receptor at the same residues *via* different kinases, the level of which is regulated by the balance of activity between kinase(s) and phosphatase(s) especially in the vicinity of GABA<sub>A</sub> receptors but not inside cells. Therefore, the time courses of the phosphorylation level appear to be dependent on the type of stimuli involved. In either case, PRIP through direct association with the GABA<sub>A</sub> receptor  $\beta$  subunit, plays an important role in recruiting proteins including the active form of Akt (this study) and protein phosphatases (PP1 and PP2A) (27, 29), which regulate the phosphorylation of the GABA<sub>A</sub> receptor  $\beta$  subunit, leading to the regulation the number of receptors on the cell surface membrane. In fact, we observed a further decrease of insulin-mediated  $I_{GABA}$  below the control level in the BFA-treated WT but not DKO neurons. This observation suggests that insulin elicits both the insertion and subsequent endocytosis of GABA<sub>A</sub> receptors and that the balance shifts to membrane insertion in insulin-stimulated WT neurons. The result also suggests that PRIP is involved in both insulin-induced membrane insertion and endocytosis of GABA<sub>A</sub> receptors. Other scaffolding molecules such as receptor for activated C kinase-1 (RACK-1) for PKC (47, 48), A-kinase anchoring protein (AKAP) 79/150 for cAMP-dependent protein kinase A (PKA) (49), and PRIP (27, 29) have been reported to determine the specificity of the specific kinase(s) or phosphatase(s) recruited to the vicinity of GABA<sub>A</sub> receptors. We still do not know the exact molecular mechanisms by which different stimuli regulate the recruitment of kinase(s) and phosphatase(s) to the vicinity of GABA<sub>A</sub>

receptors. The phosphorylation state of the scaffolding molecules may be one of the pathways that regulates the interaction among these molecules. Additionally, the molecular mechanisms by which phosphorylation of  $\beta$  subunit triggers the membrane insertion of GABA<sub>A</sub> receptors remains largely unknown.

Is there any physiological or pathological relevance of the insulin-induced membrane insertion of GABA<sub>A</sub> receptors and the involvement of PRIP? It is reported that oxygen-glucose deprivation (OGD), an ischemia-like challenge, decreases the number of cell surface GABA<sub>A</sub> receptors and thereby leads to excitotoxic cell death in cultured hippocampal neurons. Insulin treatment counteracts the OGD-induced diminishment of the number of cell surface GABA<sub>A</sub> receptors and thus prevents ischemic cell death (14). Additionally, it is reported that insulin-induced cell surface expression of GABA<sub>A</sub> receptors leads to membrane hyperpolarization in islet  $\alpha$  cells, thereby suppressing glucagon secretion (12), suggesting its involvement in diabetic pathogenesis. Another example is that interleukin-1 $\beta$  (IL-1 $\beta$ ) increases in the cell surface expression of GABA<sub>A</sub> receptors depend on the PI 3-kinase-Akt signaling pathway (50). Patients with Sepsis-associated encephalopathy (SAE), a neurological complication in sepsis, have higher plasma levels of IL-1 $\beta$ , therefore this may contribute to the cognitive dysfunction observed in SAE by altering GABAergic synaptic strength (50). It is possible that PRIP is implicated in such neuronal dysfunction and pathogenesis through the recruitment of active Akt to GABA<sub>A</sub> receptors, suggesting that PRIP could a therapeutic target.

In conclusion, we showed here that PRIP is implicated in the insulin-induced membrane insertion of GABA<sub>A</sub> receptors as it recruits active Akt to the vicinity of GABA<sub>A</sub> receptors. The subsequent complex formation may serve as the molecular basis for the efficient phosphorylation of GABA<sub>A</sub> receptors through Akt and receptor insertion into the cell surface membrane. Therefore, PRIP is a key factor in the control of the plasticity of GABAergic transmission.

## FOOTNOTES

<sup>§</sup>Current address: Department of Dental Pharmacology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8553, Japan

Keywords: Akt, GABA<sub>A</sub> receptor, membrane trafficking, phosphorylation, PRIP

Grants: This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan to M.F., T.K., and M.H.; the Cooperative Study Program of the National Institute for Physiological Sciences to T.K., J.N. and M.H.; the Japan Diabetes Foundation to T.K.; and the Pharmacological Research Foundation, Tokyo, to T.K.. M.F. is a Research Fellow supported by the Japan Society for the Promotion of Science.

<sup>‡</sup>Abbreviations: AP2, adaptor protein 2; BDNF, brain-derived neurotrophic factor; DIV, days *in vitro*; DKO, PRIP1 and PRIP2 double knockout; GABA,  $\gamma$ -aminobutyric acid; GABA<sub>A</sub> receptor,  $\gamma$ -aminobutyric acid type A receptor; GABARAP, GABA<sub>A</sub> receptor-associated protein; GST, glutathione S-transferase;  $I_{GABA}$ , GABA-induced Cl<sup>-</sup> current; PP, protein phosphatase; PRIP, phospholipase C-related but catalytically inactive protein; S. D., standard deviation; WT, wild-type

## ACKNOWLEDGEMENTS

We would like to thank Dr. U. Kikkawa (Kobe U., Japan) for kindly donating the mammalian expression vector for Akt, pECE/Akt. We thank all of the laboratory members for their critical discussion and reading the manuscript.

## REFERENCES

1. Moss, S. J., and Smart, T. G. (2001) *Nat Rev Neurosci* **2**, 240-250
2. Luscher, B., and Keller, C. A. (2004) *Pharmacol Ther* **102**, 195-221
3. Vicini, S., and Ortinski, P. (2004) *Pharmacol Ther* **103**, 109-120
4. Michels, G., and Moss, S. J. (2007) *Crit Rev Biochem Mol Biol* **42**, 3-14
5. Jacob, T. C., Moss, S. J., and Jurd, R. (2008) *Nat Rev Neurosci* **9**, 331-343
6. Kittler, J. T., Chen, G., Honing, S., Bogdanov, Y., McAinsh, K., Arancibia-Carcamo, I. L., Jovanovic, J. N., Pangalos, M. N., Haucke, V., Yan, Z., and Moss, S. J. (2005) *Proc Natl Acad Sci U S A* **102**, 14871-14876
7. Chen, G., Kittler, J. T., Moss, S. J., and Yan, Z. (2006) *J Neurosci* **26**, 2513-2521
8. Smith, K. R., McAinsh, K., Chen, G., Arancibia-Carcamo, I. L., Haucke, V., Yan, Z., Moss, S. J., and Kittler, J. T. (2008) *Neuropharmacology* **55**, 844-850
9. Kittler, J. T., Chen, G., Kukhtina, V., Vahedi-Faridi, A., Gu, Z., Tretter, V., Smith, K. R., McAinsh, K., Arancibia-Carcamo, I. L., Saenger, W., Haucke, V., Yan, Z., and Moss, S. J. (2008) *Proc Natl Acad Sci U S A* **105**, 3616-3621
10. Wan, Q., Xiong, Z. G., Man, H. Y., Ackerley, C. A., Braunton, J., Lu, W. Y., Becker, L. E., MacDonald, J. F., and Wang, Y. T. (1997) *Nature* **388**, 686-690
11. Wang, Q., Liu, L., Pei, L., Ju, W., Ahmadian, G., Lu, J., Wang, Y., Liu, F., and Wang, Y. T. (2003) *Neuron* **38**, 915-928
12. Xu, E., Kumar, M., Zhang, Y., Ju, W., Obata, T., Zhang, N., Liu, S., Wendt, A., Deng, S., Ebina, Y., Wheeler, M. B., Braun, M., and Wang, Q. (2006) *Cell Metab* **3**, 47-58
13. Vetiska, S. M., Ahmadian, G., Ju, W., Liu, L., Wymann, M. P., and Wang, Y. T. (2007) *Neuropharmacology* **52**, 146-155
14. Mielke, J. G., and Wang, Y. T. (2005) *J Neurochem* **92**, 103-113
15. Kanematsu, T., Takeya, H., Watanabe, Y., Ozaki, S., Yoshida, M., Koga, T., Iwanaga, S., and Hirata, M. (1992) *J Biol Chem* **267**, 6518-6525

16. Kanematsu, T., Misumi, Y., Watanabe, Y., Ozaki, S., Koga, T., Iwanaga, S., Ikehara, Y., and Hirata, M. (1996) *Biochem J* **313**, 319-325
17. Kanematsu, T., Yoshimura, K., Hidaka, K., Takeuchi, H., Katan, M., and Hirata, M. (2000) *Eur J Biochem* **267**, 2731-2737
18. Matsuda, M., Kanematsu, T., Takeuchi, H., Kukita, T., and Hirata, M. (1998) *Neurosci Lett* **257**, 97-100
19. Uji, A., Matsuda, M., Kukita, T., Maeda, K., Kanematsu, T., and Hirata, M. (2002) *Life Sci* **72**, 443-453
20. Otsuki, M., Fukami, K., Kohno, T., Yokota, J., and Takenawa, T. (1999) *Biochem Biophys Res Commun* **266**, 97-103
21. Kanematsu, T., Jang, I. S., Yamaguchi, T., Nagahama, H., Yoshimura, K., Hidaka, K., Matsuda, M., Takeuchi, H., Misumi, Y., Nakayama, K., Yamamoto, T., Akaike, N., Hirata, M., and Nakayama, K. (2002) *EMBO J* **21**, 1004-1011
22. Mizokami, A., Kanematsu, T., Ishibashi, H., Yamaguchi, T., Tanida, I., Takenaka, K., Nakayama, K. I., Fukami, K., Takenawa, T., Kominami, E., Moss, S. J., Yamamoto, T., Nabekura, J., and Hirata, M. (2007) *J Neurosci* **27**, 1692-1701
23. Coyle, J. E., and Nikolov, D. B. (2003) *Neuroscientist* **9**, 205-216
24. Chen, Z. W., and Olsen, R. W. (2007) *J Neurochem* **100**, 279-294
25. Yoshimura, K., Takeuchi, H., Sato, O., Hidaka, K., Doira, N., Terunuma, M., Harada, K., Ogawa, Y., Ito, Y., Kanematsu, T., and Hirata, M. (2001) *J Biol Chem* **276**, 17908-17913
26. Yanagihori, S., Terunuma, M., Koyano, K., Kanematsu, T., Ho Ryu, S., and Hirata, M. (2006) *Adv Enzyme Regul* **46**, 203-222
27. Terunuma, M., Jang, I. S., Ha, S. H., Kittler, J. T., Kanematsu, T., Jovanovic, J. N., Nakayama, K. I., Akaike, N., Ryu, S. H., Moss, S. J., and Hirata, M. (2004) *J Neurosci* **24**, 7074-7084
28. Kanematsu, T., Fujii, M., Mizokami, A., Kittler, J. T., Nabekura, J., Moss, S. J., and Hirata, M. (2007) *J Neurochem* **101**, 898-905
29. Kanematsu, T., Yasunaga, A., Mizoguchi, Y., Kuratani, A., Kittler, J. T., Jovanovic, J. N., Takenaka, K., Nakayama, K. I., Fukami, K., Takenawa, T., Moss, S. J., Nabekura, J., and Hirata, M. (2006) *J Biol Chem* **281**, 22180-22189
30. Kanematsu, T., Takeuchi, H., Terunuma, M., and Hirata, M. (2005) *Mol Cells* **20**, 305-314
31. Kanematsu, T., Mizokami, A., Watanabe, K., and Hirata, M. (2007) *J Pharmacol Sci* **104**, 285-292
32. Klausner, R. D., Donaldson, J. G., and Lippincott-Schwartz, J. (1992) *J Cell Biol* **116**, 1071-1080
33. Chardin, P., and McCormick, F. (1999) *Cell* **97**, 153-155
34. Connolly, C. N., Krishek, B. J., McDonald, B. J., Smart, T. G., and Moss, S. J. (1996) *J Biol Chem* **271**, 89-96
35. Konishi, H., Matsuzaki, H., Tanaka, M., Ono, Y., Tokunaga, C., Kuroda, S., and Kikkawa, U. (1996) *Proc Natl Acad Sci U S A* **93**, 7639-7643
36. Mizoguchi, Y., Ishibashi, H., and Nabekura, J. (2003) *J Physiol* **548**, 703-709
37. Kakazu, Y., Akaike, N., Komiyama, S., and Nabekura, J. (1999) *J Neurosci* **19**, 2843-2851
38. Nabekura, J., Ueno, T., Okabe, A., Furuta, A., Iwaki, T., Shimizu-Okabe, C., Fukuda, A., and Akaike, N. (2002) *J Neurosci* **22**, 4412-4417
39. Fujii, M., and York, J. D. (2005) *J Biol Chem* **280**, 1156-1164
40. Wang, Q., Somwar, R., Bilan, P. J., Liu, Z., Jin, J., Woodgett, J. R., and Klip, A. (1999) *Mol Cell Biol* **19**, 4008-4018
41. Jovanovic, J. N., Thomas, P., Kittler, J. T., Smart, T. G., and Moss, S. J. (2004) *J Neurosci* **24**, 522-530
42. Favre, B., Turowski, P., and Hemmings, B. A. (1997) *J Biol Chem* **272**, 13856-13863
43. Alessi, D. R., and Downes, C. P. (1998) *Biochim Biophys Acta* **1436**, 151-164

44. van der Heide, L. P., Ramakers, G. M., and Smidt, M. P. (2006) *Prog Neurobiol* **79**, 205-221
45. Kong, D., and Yamori, T. (2008) *Cancer Sci* **99**, 1734-1740
46. Goto, H., Terunuma, M., Kanematsu, T., Misumi, Y., Moss, S. J., and Hirata, M. (2005) *Mol Cell Neurosci* **30**, 197-206
47. Brandon, N. J., Uren, J. M., Kittler, J. T., Wang, H., Olsen, R., Parker, P. J., and Moss, S. J. (1999) *J Neurosci* **19**, 9228-9234
48. Brandon, N. J., Jovanovic, J. N., Smart, T. G., and Moss, S. J. (2002) *J Neurosci* **22**, 6353-6361
49. Brandon, N. J., Jovanovic, J. N., Colledge, M., Kittler, J. T., Brandon, J. M., Scott, J. D., and Moss, S. J. (2003) *Mol Cell Neurosci* **22**, 87-97
50. Serantes, R., Arnalich, F., Figueroa, M., Salinas, M., Andres-Mateos, E., Codoceo, R., Renart, J., Matute, C., Cavada, C., Cuadrado, A., and Montiel, C. (2006) *J Biol Chem* **281**, 14632-14643

### FIGURE LEGENDS

Figure 1. Electrophysiological analysis of  $I_{GABA}$  in insulin stimulated hippocampal CA1 neurons and phosphorylation of the GABA<sub>A</sub> receptor  $\beta$ 2/3 subunit.

(A) Effect of insulin on  $I_{GABA}$ . Electrophysiological experiments were performed using acutely prepared hippocampal CA1 neurons from WT (closed circles, n=5) or DKO (open circles, n=5) mice. GABA (3  $\mu$ M) was applied for 15 sec (3 min interval), and whole cell currents were recorded. Insulin (1  $\mu$ M) was applied for the time period indicated by the double-headed arrow in graph. Upper panel shows representative GABA-induced current traces at 0 min or 15 min after insulin stimulation of WT or DKO neurons. Vertical and horizontal scales show 200 pA and 15 s, respectively. The graph shows the amplitude of  $I_{GABA}$  normalized to that seen without insulin. All data are represented as means  $\pm$  S.D.. Significance was determined using the Student's *t* test (\*\* $p$ <0.01, compared to the results from DKO). (B) Phosphorylation of the  $\beta$  subunit in response to insulin stimulation. The cultured cortical neurons (DIV. 14-18) of the WT or DKO mice were metabolically labeled with [<sup>32</sup>P]orthophosphates for 4 hr. The neurons were stimulated with 500 nM insulin for the indicated time, and then the cell lysates were subjected to immunoprecipitation using an anti-GABA<sub>A</sub> receptor  $\beta$ 2/3 subunit antibody. The immunocomplexes were separated by SDS-PAGE and then subjected to autoradiography. Phosphorylated bands were detected using BAS2500. The autoradiograph represents one of four independent experiments. The other experiments gave similar results. The graph shows quantitative data concerning the phosphorylation of the GABA<sub>A</sub> receptor  $\beta$ 2/3 subunit of WT (closed circles) or DKO (open circles) neurons. As mentioned above, [<sup>32</sup>P] incorporation was analyzed, because the phospho-specific antibody currently available recognizes the di-phosphorylated  $\beta$ 3 subunit at both S408 and S409 (29, 41), and insulin causes a single phosphorylation at S410 or S409 of  $\beta$ 2 or  $\beta$ 3 subunit, respectively (11, 12). Data are represented as means  $\pm$  S.D. (n=4). Significance was determined using the Student's *t* test (\* $p$ <0.05, \*\* $p$ <0.01, compared to the results from DKO).

Figure 2. Effect of okadaic acid or wortmanin on the insulin-potentiation of  $I_{GABA}$ .

(A) Effect of okadaic acid on the insulin-potentiation of  $I_{GABA}$ . Neurons from WT (left panel, closed triangles, n=8) or DKO (right panel, open triangles, n=3) mice were pretreated with 10  $\mu$ M of okadaic acid, an inhibitor of the protein phosphatases PP1 and PP2A (42), for 15 min and throughout the experiment. The experiment was performed as shown in Figure 1A except for the okadaic acid treatment. All data are represented as means  $\pm$  S.D.. The  $I_{GABA}$  from WT (left panel, closed circles, dashed line) or DKO (right panel, open circles, dashed line) mice without okadaic acid (none), which were taken from Figure 1A, are also shown as references. (B) The effect of wortmannin on the insulin-potentiation of  $I_{GABA}$ . Neurons from WT (left panel, closed squares, n=6) or DKO (right panel, open squares, n=3) mice were pretreated with 100 nM of wortmannin, a potent PI 3-kinase inhibitor (45), for 15 min and throughout the experiment. The

experiments were performed as shown in Figure 1A except for the wortmannin treatment. All data are represented as means  $\pm$  S.D.. The  $I_{GABA}$  from WT (left panel, closed circles, dashed line) or DKO (right panel, open circles, dashed line) mice without wortmannin (none), which were taken from those shown in Figure 1A, are also shown as references. Double-headed arrows indicate the period of insulin stimulation. Significance was determined using the Student's *t* test (\*\* $p$ <0.01 from the results obtained in the absence of the drug). none; no addition, OA; okadaic acid, Wort.; wortmannin.

Figure 3. PRIP deficiency caused little changes in the expression level of molecules possibly involved in insulin signaling

(A) Western blotting analysis of the expression level of insulin signaling molecules. WT or DKO cortical neurons were cultured for 14-18 days and then stimulated with 500 nM insulin for the indicated time. The cell lysates were analyzed by Western blotting using the indicated antibodies shown on the left. The blot shown is a typical result from six experiments. (B) Western blotting analysis of Akt activation. The WT or DKO cortical cell lysates were prepared in the same way as described above and analyzed by Western blotting using anti-phosphoAkt antibodies. The blot and graph shown are a typical result and the summary of 7 experiments, respectively. The densities of phosphoAkt at T308 (left panel) and S473 (right panel) relative to the total amount of Akt are shown. The filled and open columns represent the results obtained for WT and DKO mice, respectively. (C) Akt kinase activity assayed *in vitro*. The cell lysates of WT (filled columns) or DKO (open columns) neurons stimulated with 500 nM insulin for 15 min were subjected to immunoprecipitation using an anti-Akt antibody. The immunocomplexes were subjected to an Akt kinase assay using crosstide as a substrate and [ $\gamma$ - $^{32}$ P]ATP. Data are represented as means  $\pm$  S.D. (n=3). Significance was determined by Student's *t* test (\* $p$ <0.05, \*\* $p$ <0.01, compared with the result before insulin stimulation), but no difference was detected between WT and DKO.

Figure 4. Complex formation among GABA<sub>A</sub> receptor, PRIP, and Akt

(A) GABA<sub>A</sub> receptors were immunoprecipitated using an anti-GABA<sub>A</sub> receptor  $\beta$ 2/3 subunit antibody from WT or DKO brain lysates. The cell lysates (left panel) and immunoprecipitates (right panel) were analyzed by Western blotting using the indicated antibodies shown on the left. The blots shown are from one of three independent experiments. The other experiments gave similar results. (B) The MYC-tagged GABA<sub>A</sub> receptor subunits ( $\alpha$ 1,  $\beta$ 2, and  $\gamma$ 2S) and Akt with or without PRIP1 were exogenously expressed in HEK293 cells. After stimulation with 500 nM insulin for the indicated time, the cell lysates were subjected to immunoprecipitation using an anti-MYC antibody. The immunocomplexes were separated by SDS-PAGE and then analyzed by Western blotting using an anti-Akt antibody. The cell lysates were also analyzed by Western blotting using the indicated antibodies. The blots shown are one of three independent experiments. The other experiments gave similar results. The graph shows quantitative data concerning the Akt co-precipitated with GABA<sub>A</sub> receptors in PRIP expressing (filled columns) or control (open columns) cells. Significance was determined using the Student's *t* test (\*\* $p$ <0.01 from the control cells without exogenous PRIP1). (C) HEK293 cells were transfected with Akt and GST-PRIP1 (or GST) expression plasmids. After stimulation with 500 nM insulin for 15 min, GST-fusion proteins were precipitated with glutathione Sepharose™ 4B. The protein complexes were separated by SDS-PAGE and then analyzed by Western blotting using an anti-Akt antibody, an anti-phosphoAkt (T308), and an anti-GST polyclonal antibody. The cell lysates were also analyzed by Western blotting using the indicated antibodies. The blots shown are one of three independent experiments. The other experiments gave similar results.

Figure 5. Effect of PRIP1 553-565 peptide on insulin-potentiation of  $I_{GABA}$  in hippocampal CA1 neurons

(A) The PRIP1 553-565 peptide (3  $\mu$ g/ml) (open triangles, n=3), which diminishes the binding between PRIP and the GABA<sub>A</sub> receptor  $\beta$  subunit (29), or its scramble peptide (3  $\mu$ g/ml) (closed triangles, n=3) were introduced using a patch pipette. The experiment was performed in

the same way as that shown in Figure 1A. A double-headed arrow indicates the time period of insulin application. Data are represented by the means  $\pm$  S.D.. The  $I_{GABA}$  from WT (closed circles, dashed line) or DKO (open circles, dashed line) mice without the peptide, which were taken from those shown in Figure 1A, are also shown as references. (B) The graph shows the potentiation of  $I_{GABA}$  at 15 min after insulin stimulation in WT (filled columns) or DKO (open column) neurons with or without the indicated peptides (Pep.; PRIP1 553-565 peptides, Scr.; PRIP1 553-565 scramble peptides, (-); no peptides). Data are represented as means  $\pm$  S.D.. Significance was determined using the Student's *t* test (\* $p$ <0.05, \*\* $p$ <0.01, between indicated two columns).


Figure 6. Effect of BFA on insulin-potentiation of  $I_{GABA}$ .

Neurons from either WT (left panel, closed triangles, n=3) or DKO (right panel, open triangles, n=3) were pretreated with 5  $\mu$ g/ml of BFA, which inhibits anterograde trafficking from the ER to the Golgi apparatus (32, 33) for 15 min and throughout the experiment. The experiment was performed in the same way as that described for Figure 1A. All data are represented as means  $\pm$  S.D.. The  $I_{GABA}$  from either WT or DKO without BFA, which were taken from those shown in Figure 1A, are also shown as references. Significance was determined using the Student's *t* test (\*\* $p$ <0.01, from the results obtained in the absence of the drug). Double-headed arrows indicate the time period of insulin stimulation. none; no drug, BFA; brefeldin A.


Figure 7. Schematic representation of the role of PRIP in insulin-induced membrane insertion of  $GABA_A$  receptors.



(A) Insulin stimulation induces Akt activation in a PI 3-kinase-dependent manner. Subsequent phosphorylation of the  $\beta$  subunits of  $GABA_A$  receptors by Akt is facilitated by PRIP through the ternary complex formation with activated Akt and  $\beta$  subunit, which triggers an enhancement of the insertion of  $GABA_A$  receptors into the postsynaptic membrane. (B) Absence of PRIP fails in making activated Akt accessible to  $\beta$  subunit. Arrows indicate the signaling pathways to activate downstream target. Dashed arrows indicate the complex formation. White arrow indicates membrane insertion of  $GABA_A$  receptor. InsR; insulin receptor,  $GABA_A R$ ;  $GABA_A$  receptor, PI3K; PI 3-kinase, PIP<sub>2</sub>; phosphatidylinositol 4,5-bisphosphate, PIP<sub>3</sub>; phosphatidylinositol 3,4,5-trisphosphate, PRIP; PLC-related but catalytically inactive protein. Circled P indicates the phosphorylation.

(A)







(B)














(A)




(B)





(A)



(B)

